Virax Biolabs: Funding, Investors & Team (Oct 2026)
Virax Biolabs is a biotech company focused on preventing, detecting, and diagnosing viral diseases. Established in 2013, they generate revenue through developing and distributing in vitro diagnostic test kits. They are working on an immunology platform utilizing T-Cell testing, which is effective in diagnosing and treating COVID-19, Hepatitis B, Malaria, and Human Papilloma Virus. Their goal is to facilitate the transition to the 'new normal' during and after the pandemic by providing cutting-edge medical equipment and technology. Virax Biolabs is also acquiring innovative biosensor technology to create advanced point-of-care biomarker testing devices that rival traditional lab-based ELISA tests in accuracy.
Virax Biolabs has raised $13.8M across 3 funding rounds on record, the most recent an undisclosed round of $5.0M announced in Dec 2025.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Virax Biolabs Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Virax Biolabs Funding Rounds
Virax Biolabs raised $3.8M in an undisclosed round announced in Nov 2022.
1.8 years later, an undisclosed round of $5.0M was announced in Aug 2024.
1.3 years later, an undisclosed round of $5.0M was announced in Dec 2025.
Virax Biolabs Founders and Leadership Team
No contact details are on record for this team yet.
Virax Biolabs Funding Compared to Other Biotechnology Startups
Virax Biolabs' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Virax Biolabs in Biotechnology and London
Companies Similar to Virax Biolabs
Microbiotica develops treatments involving live bacteria found in the human microbiome, aiming to identify…
OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop…
HydRegen, based in Oxford, UK, is a biotech firm that offers eco-friendly alternatives for the production of…
R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug…
The perfect package for any general surgical trainee or resident. Progress from beginner to advanced surgical…
Argonaute RNA company research projects build on existing intellectual property.
An innovative C elegans company that serves the biotech, nutrition, and other industries and fields of study…
ViaNautis, previously known as SomaServe, was established in 2018 as a separate entity from UCL under the…
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
Virax Biolabs Funding FAQs
What does Virax Biolabs do?
Virax Biolabs is a biotech company focused on preventing, detecting, and diagnosing viral diseases. Established in 2013, they generate revenue through developing and distributing in vitro diagnostic test kits. They are working on an immunology platform utilizing T-Cell testing, which is effective in diagnosing and treating COVID-19, Hepatitis B, Malaria, and Human Papilloma Virus. Their goal is to facilitate the transition to the 'new normal' during and after the pandemic by providing cutting-edge medical equipment and technology. Virax Biolabs is also acquiring innovative biosensor technology to create advanced point-of-care biomarker testing devices that rival traditional lab-based ELISA tests in accuracy.
How much funding has Virax Biolabs raised?
Virax Biolabs has raised $13.8M across 3 rounds on record. The most recent is an undisclosed round of $5.0M announced in Dec 2025.
When did Virax Biolabs last raise funding?
Virax Biolabs' most recent funding round on record is an undisclosed round of $5.0M, announced in Dec 2025.
Who founded Virax Biolabs?
FundedIQ lists Mark Ternouth (Founder), Tomasz George (Founder) at Virax Biolabs.
Where is Virax Biolabs headquartered?
Virax Biolabs is based in London, England, United Kingdom.
How many employees does Virax Biolabs have?
Virax Biolabs is in the 11-50 employee band.
How does Virax Biolabs' funding compare to other Biotechnology startups?
Virax Biolabs' latest round of $5.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Virax Biolabs Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Virax Biolabs is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.